Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-4 (canceled)

Claim 5 (currently amended): A compound of the formula (V):



or its pharmaceutically acceptable salt thereof, wherein:

(a) B, D and E are independently O;

(b) G is OR^{11}, $NR^{11}R^{12}$ or SR^{11};

(c) R^1, R^2, R^3, R^4, R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, ~~cycloalkyl, cycloalkenyl, cycloalkynyl~~, aryl, alkaryl, arylalkyl, ~~heterocyclic, heteroaryl, heteroaromatic,~~; a moiety selected from optionally substituted furyl, furanyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4-thiadiazolyl, isooxazolyl, pyrrolyl, quinazolinyl, cinnolinyl, phthalazinyl, xanthinyl, hypoxanthinyl, thiophene, furan, pyrrole, isopyrrole, pyrazole, and imidazole; ~~alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a natural or synthetic amino acid, a natural or synthetic carbohydrate or XR^9 (wherein X = O, S or NR^{10})~~; and

(d) each R^7, R^8, R^9, R^{10}, R^{11} and R^{12} is independently hydrogen, alkyl, alkenyl, alkynyl, ~~cycloalkyl, cycloalkenyl, cycloalkynyl~~, aryl, alkaryl, arylalkyl, ~~heterocyclic, heteroaryl, heteroaromatic,~~; a moiety selected from optionally substituted furyl, furanyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4-thiadiazolyl, isooxazolyl, pyrrolyl, quinazolinyl, cinnolinyl, phthalazinyl, xanthinyl, hypoxanthinyl, thiophene, furan, pyrrole, isopyrrole, pyrazole, and imidazole ~~alkcarbonyl, a natural or synthetic amino acid or a natural or synthetic carbohydrate~~.

Claims 6-22 (canceled)

Claim 23 (Currently amended): A pharmaceutical composition for the treatment of an inflammatory disorder in a host comprising an effective treatment amount of a compound according to claim 5 ~~optionally~~ in a pharmaceutically acceptable carrier or diluent.

Claim 24 (canceled)

Claim 25 (Previously presented): A compound of formula:



or its pharmaceutically acceptable salt thereof.

Claim 26 (currently amended): A pharmaceutical composition for the treatment of an inflammatory disorder in a host comprising an effective treatment amount of a compound of formula:



or its pharmaceutically acceptable salt thereof, wherein:

(a) B, D and E are independently O;

(b) G is OR^{11}, $NR^{11}R^{12}$ or SR^{11};

(c) R^1, R^2, R^3, R^4, R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, ~~cycloalkyl, cycloalkenyl, cycloalkynyl~~, aryl, alkaryl, arylalkyl, ~~heterocyclic, heteroaryl, heteroaromatic,~~; a moiety selected from optionally substituted furyl, furanyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4-thiadiazolyl, isooxazolyl, pyrrolyl, quinazolinyl, cinnolinyl, phthalazinyl, xanthinyl, hypoxanthinyl, thiophene, furan, pyrrole, isopyrrole, pyrazole, and imidazole ~~alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a a natural or synthetic amino acid, a natural or synthetic carbohydrate or XR^9 (wherein X = O, S or NR^{10});~~ and

~~(d)~~ each R^7, R^8, R^9, R^{10}, R^{11} and R^{12} is independently hydrogen, alkyl, alkenyl, alkynyl, ~~cycloalkyl, cycloalkenyl, cycloalkynyl~~, aryl, alkaryl, arylalkyl, ~~heterocyclic, heteroaryl, heteroaromatic,~~; a moiety selected from optionally substituted furyl, furanyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4-thiadiazolyl, isooxazolyl, pyrrolyl, quinazolinyl, cinnolinyl, phthalazinyl, xanthinyl,

hypoxanthinyl, thiophene, furan, pyrrole, isopyrrole, pyrazole, and imidazole; ~~alkcarbonyl, a natural or synthetic amino acid or a natural or synthetic carbohydrate~~

~~optionally~~ in a pharmaceutically acceptable carrier in combination with other anti-inflammatory agents.

Claim 27 (Currently Amended): The pharmaceutical composition of claim 23, ~~24,~~ or 26, wherein the host is a human.

Claim 28 (Currently Amended): The pharmaceutical composition of claim 23, ~~24,~~ or 26, wherein the compound is in the form of a dosage unit.

Claim 29 (Previously presented): The pharmaceutical composition according to claim 28, wherein the dosage unit contains 7 to 3000 mg of the compound.

Claim 30 (Previously presented): The pharmaceutical composition according to claim 28, wherein the dosage unit contains 70 to 1400 mg of the compound.

Claim 31 (Previously presented): The pharmaceutical composition according to claim 28, wherein the dosage unit contains 50-500 mg of the compound.

Claim 32 (Previously presented): The pharmaceutical composition according to claim 28, wherein the dosage unit is a tablet or capsule.

Claim 33 (Previously presented): The pharmaceutical composition according to claim 26, wherein the anti-inflammatory agent is selected from the group consisting of heparin, frusemide, ranitidine, an agent that effects respiratory function, immunosuppressive agents, IV gamma globulin, troleandomycin, cyclosporin (Neoral), methotrexate, FK-506, gold compounds, platelet activating factor (PAF), leukotriene-D_4-receptor antagonists), Ziflo (zileuton), leukotriene C_1 or C_2 antagonists and inhibitors of leukotriene synthesis, and an inducible nitric oxide synthase inhibitor.

Claim 34 (Previously presented): The pharmaceutical composition of claim 26, wherein the anti-inflammatory agent is selected from the group consisting β_2-adrenergic agonist (β agonists).

Claim 35 (Previously presented): The pharmaceutical composition of claim 34, wherein the β agonist is selected from the group consisting of albuterol (salbutamol, Proventil, Ventolin), terbutaline, Maxair (pirbuterol), Serevent (salmeterol), epinephrine, metaproterenol (Alupent, Metaprel), Brethine (Bricanyl, Brethaire, terbutaline sulfate), Tornalate (bitolterol), isoprenaline, ipratropium bromide, bambuterol hydrochloride, bitolterol meslyate, broxaterol, carbuterol hydrochloride, clenbuterol hydrochloride, clorprenaline hydrochloride, efirmoterol fumarate, ephedra (source of alkaloids), ephedrine (ephedrine hydrochloride, ephedrine sulfate), etafedrine hydrochloride, ethylnoradrenaline hydrochloride, fenoterol hydrochloride, hexoprenaline hydrochloride, isoetharine hydrochloride, isoprenaline, mabuterol, methoxyphenamine hydrochloride, methylephedrine hydrochloride, orciprenaline sulphate, phenylephrine acid tartrate, phenylpropanolamine (phenylpropanolamine polistirex, phenylpropanolamine sulphate), pirbuterol acetate, procaterol hydrochloride, protokylol hydrochloride, psuedoephedrine (psuedoephedrine polixtirex, psuedoephedrine tannate, psuedoephedrine hydrochloride, psuedoephedrine sulphate), reproterol hydrochloride, rimiterol hydrobromide, ritodrine hydrochloride, salmeterol xinafoate, terbutaline sulphate, tretoquinol hydrate and tulobuterol hydrochloride.

Claim 36 (Previously presented): The pharmaceutical composition according to claim 26, wherein the anti-inflammatory agent is selected from the group consisting of a corticosteroid, antihistamine (H_1 receptor antagonists), xanthines and methylxanthines, anticholinergic agents (antimuscarinic agents), and phosphodiesterase inhibitors.

Claim 37 (Currently Amended): A pharmaceutical composition for the treatment of an inflammatory disorder in a host comprising an effective treatment amount of a compound of formula:



or its pharmaceutically acceptable salt thereof, ~~optionally~~ in a pharmaceutically acceptable carrier or diluent.

Claim 38 (Currently Amended): A pharmaceutical composition for the treatment of an inflammatory disorder in a host comprising an effective treatment amount of a compound of formula:



or a pharmaceutically acceptable salt thereof; ~~optionally~~ in a pharmaceutically acceptable carrier, in combination with another anti-inflammatory agent.

Claim 39 (Previously presented): The pharmaceutical composition of claim 37 or 38, wherein the compound is in the form of a dosage unit.

Claim 40 (Previously presented): The pharmaceutical composition of claim 39, wherein the dosage unit contains 7 to 3000 mg of the compound.

Claim 41 (Previously presented): The pharmaceutical composition of claim 39, wherein the dosage unit contains 70 to 1400 mg of the compound.

Claim 42 (Previously presented): The pharmaceutical composition of claim 39, wherein the dosage unit contains 50-500 mg of the compound.

Claim 43 (Previously presented): The pharmaceutical composition of claim 39, wherein the dosage unit is a tablet or capsule.

Claim 44 (Previously presented): The pharmaceutical composition of claim 38, wherein the anti-inflammatory agent is selected from the group consisting of heparin, frusemide, ranitidine, an agent that effects respiratory function, immunosuppressive agents, IV gamma globulin, troleandomycin, cyclosporin (Neoral), methotrexate, FK-506, gold compounds, platelet activating factor (PAF), leukotriene-D_4-receptor antagonists), Ziflo (zileuton), leukotriene C_1 or C_2 antagonists and inhibitors of leukotriene synthesis, and an inducible nitric oxide synthase inhibitor.

Claim 45 (Previously presented): The pharmaceutical composition of claim 38, wherein the anti-inflammatory agent is selected from the group consisting β_2-adrenergic agonist (β agonists).

Claim 46 (Previously presented): The pharmaceutical composition of claim 45, wherein the β agonist is selected from the group consisting of albuterol (salbutamol, Proventil, Ventolin), terbutaline, Maxair (pirbuterol), Serevent (salmeterol), epinephrine, metaproterenol (Alupent, Metaprel), Brethine (Bricanyl, Brethaire, terbutaline sulfate), Tornalate (bitolterol), isoprenaline, ipratropium bromide, bambuterol hydrochloride, bitolterol meslyate, broxaterol, carbuterol hydrochloride, clenbuterol hydrochloride, clorprenaline hydrochloride, efirmoterol fumarate, ephedra (source of alkaloids), ephedrine (ephedrine hydrochloride, ephedrine sulfate), etafedrine hydrochloride, ethylnoradrenaline hydrochloride, fenoterol hydrochloride, hexoprenaline hydrochloride, isoetharine hydrochloride, isoprenaline, mabuterol, methoxyphenamine hydrochloride, methylephedrine hydrochloride, orciprenaline sulphate, phenylephrine acid tartrate, phenylpropanolamine (phenylpropanolamine polistirex, phenylpropanolamine sulphate), pirbuterol acetate, procaterol hydrochloride, protokylol hydrochloride, psuedoephedrine (psuedoephedrine polixtirex, psuedoephedrine tannate, psuedoephedrine hydrochloride, psuedoephedrine sulphate), reproterol hydrochloride, rimiterol hydrobromide, ritodrine hydrochloride, salmeterol xinafoate, terbutaline sulphate, tretoquinol hydrate and tulobuterol hydrochloride.

Claim 47 (Previously presented): The pharmaceutical composition of claim 38, wherein the anti-inflammatory agent is selected from the group consisting of a corticosteroid, antihistamine (H_1 receptor antagonists), xanthines and methylxanthines, anticholinergic agents (antimuscarinic agents), and phosphodiesterase inhibitors.

Claim 48 (Previously presented): The pharmaceutical composition of any one of claims 37 or 38, wherein the host is a human.

Claim 49 (New) The compound of claim 5 wherein G is OR^{11}.

Claim 50 (New) The compound of claim 5 wherein G is $NR^{11}R^{12}$.

Claim 51 (New) The compound of claim 5 wherein G is SR^{11}.

Claim 52 (New) The compound of claim 5 wherein at least one of R^1, R^2, R^3, R^4, R^5 and R^6 is an alkyl group.

Claim 53 (New) The compound of claim 5 wherein at least one of R^1, R^2, R^3, R^4, R^5 and R^6 is an alkenyl group.

Claim 54 (New) The compound of claim 5 wherein at least one of R^1, R^2, R^3, R^4, R^5 and R^6 is an alkynyl group.

Claim 55 (New) The compound of claim 5 wherein at least one of R^1, R^2, R^3, R^4, R^5 and R^6 is an aryl group.

Claim 56 (New) The compound of claim 5 wherein at least one of R^1, R^2, R^3, R^4, R^5 and R^6 is an alkaryl group.

Claim 57 (New) The compound of claim 5 wherein at least one of R^1, R^2, R^3, R^4, R^5 and R^6 is an arylalkyl group.

Claim 58 (New) The compound of claim 5 wherein R^7, R^8, R^9, R^{10}, R^{11} and R^{12} are all hydrogen.

Claim 59 (New) The compound of claim 5 wherein at least one of R^7, R^8, R^9, R^{10}, R^{11} and R^{12} is an alkyl group.

Claim 60 (New) The compound of claim 5 wherein at least one of R^7, R^8, R^9, R^{10}, R^{11} and R^{12} is an alkenyl group.

Claim 61 (New) The compound of claim 5 wherein at least one of R^7, R^8, R^9, R^{10}, R^{11} and R^{12} is an alkynyl group.

Claim 62 (New) The compound of claim 5 wherein at least one of R^7, R^8, R^9, R^{10}, R^{11} and R^{12} is an aryl group.

Claim 63 (New) The compound of claim 5 wherein at least one of R^7, R^8, R^9, R^{10}, R^{11} and R^{12} is an alkaryl group.

Claim 64 (New) The compound of claim 5 wherein at least one of R^7, R^8, R^9, R^{10}, R^{11} and R^{12} is an arylalkyl group.